TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.

E Jonasch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.